1.本技术涉及生物医药领域,具体的涉及一种vegf-trap多肽及其应用。 背景技术: 2.肿瘤的无限制侵袭性生长及其转移依赖于血管生成。血管内皮生长因子(vascularendothelial growth factor,vegf)是血管形成作用最强的正性调控因子之一,它通过与其特异性受体——血管内皮生长因子受体(vascular endothelial growth factor receptor,...
“Y”字型的两臂为功能特异性结合位点,分别取自人的血管内皮生长因子受体1(VEGFR1)的第2活性区域,和受体2(VEGFR2)的第3活性区域,两个活性区域接合成一个高亲和力的蛋白分子片断;将相同的两个蛋白分子片断连接在一起形成“Y”字型的双臂形式(图1的上图);第二部分是取自人的免疫球蛋白G1 (IgG1)的Fc片断(图...
“Y”字型的两臂为功能特异性结合位点,分别取自人的血管内皮生长因子受体1(VEGFR1)的第2活性区域,和受体2(VEGFR2)的第3活性区域,两个活性区域接合成一个高亲和力的蛋白分子片断;将相同的两个蛋白分子片断连接在一起形成“Y”字型的双臂形式(图1的上图);第二部分是取自人的免疫球蛋白G1 (IgG1)的Fc片断(图...
In contrast to the antibody-based VEGF binding strategy used by ranibizumab and bevacizumab, the VTE incorporates the second binding domain of the VEGFR-1 receptor and the third domain of the VEGFR-2 receptor.1 By fusing these extracellular protein sequences to the Fc segment of a human IgG ...
VEGF Trap is comprised of portions of the human VEGF receptor VEGFR1 (Flt-1) and VEGFR2 (KDR) extracellular domains fused to human IgG1 Fc. METHODS: In this phase I trial, successive cohorts of pts with relapsed or refractory solid tumors received a single sc dose of VEGF Trap, followed ...
2.根据权利要求1所述的VEGF-trap多肽,其与SEQ ID NO.8所示的序列相比,在第153 位包含氨基酸的取代。 3.根据权利要求1-2中任一项所述的VEGF-trap多肽,其与SEQ ID NO.8所示的序列相 比,在第156位包含氨基酸的取代。 4.根据权利要求1-3中任一项所述的VEGF-trap多肽,其包含选自下组的氨基酸取代: a)K148...
RC28, a novel recombinant dual decoy receptor IgG1 Fc-fusion protein, can block VEGFA and FGF-2 simultaneously. It is designed for the treatment of neovascular age-related macular degeneration and other pathological ocular neovascularization. The present study investigated the prevention efficacy of ...
免疫融合蛋白Ultra-VEGF-trap若进入体内可以阻碍VEGF-A、VEGF-B、VEGF-C和VEGF-D与它们的受体VEGFR-1(fms-like tyrosine kinase,Flt-1)、VEGFR-2(kinase insertdomain containing receptor,KDR/Flk-1)和VEGFR-3(Flt-4)的结合,抑制肿瘤组织新生血管和淋巴管的生成,达到抑制肿瘤的生长和通过淋巴系统转移的目的,...
vegf trap is a potent vegf inhibitor comprising ligand-binding portions of human vegf receptor 1 (vegfr1) and vegfr2 fused to the fc segment of human igg1 (figure 1). vegf trap binds and neutralizes multiple isoforms of vegf-a (dissociation constant of approximately 1pm) as well as the ...
Here we demonstrate that when Dll4 inhibition is combined with a soluble VEGF decoy receptor (VEGF Trap, aflibercept), ascites is virtually unmeasurable and tumor burden is strikingly inhibited in an orthotopic immunodeficient mouse model of advanced human ovarian cancer with ascites. Four groups of...